# Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

> **NCT02016872** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Non-Small-Cell-Lung Cancer (NSCLC)

## Interventions

- **DRUG:** 18F-FMISO
- **OTHER:** PET/CT

## Key facts

- **NCT ID:** NCT02016872
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-16
- **Primary completion:** 2024-07-08
- **Final completion:** 2024-07-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02016872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02016872, "Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02016872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*